Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $74.1 million.

  • Bicycle Therapeutics' Non-Current Deffered Revenue fell 2422.38% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 2422.38%. This contributed to the annual value of $91.5 million for FY2024, which is 1701.11% down from last year.
  • As of Q3 2025, Bicycle Therapeutics' Non-Current Deffered Revenue stood at $74.1 million, which was down 2422.38% from $82.9 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Non-Current Deffered Revenue registered a high of $115.1 million during Q2 2023, and its lowest value of $25.3 million during Q2 2021.
  • For the 5-year period, Bicycle Therapeutics' Non-Current Deffered Revenue averaged around $71.7 million, with its median value being $82.2 million (2025).
  • Per our database at Business Quant, Bicycle Therapeutics' Non-Current Deffered Revenue skyrocketed by 16586.9% in 2023 and then plummeted by 2422.38% in 2025.
  • Over the past 5 years, Bicycle Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $52.1 million in 2021, then dropped by 20.38% to $41.5 million in 2022, then soared by 165.87% to $110.2 million in 2023, then dropped by 17.01% to $91.5 million in 2024, then dropped by 18.97% to $74.1 million in 2025.
  • Its last three reported values are $74.1 million in Q3 2025, $82.9 million for Q2 2025, and $82.2 million during Q1 2025.